Success Stories: No RFE, Fast Approval: NAILG Secured EB-1A for Leading Researcher in Human Liver Disease
Client’s Testimonial:
“I wanted to take a moment to sincerely thank you for your exceptional support and guidance throughout the I-140 EB1A petition process. I am thrilled to know that the petition has been approved, and I truly could not have reached this milestone without your expertise, diligence, and encouragement. Your deep knowledge of the process, meticulous attention to detail, and unwavering commitment to presenting the strongest possible case were evident every step of the way. I greatly appreciate the time you invested in understanding my background and helping to frame my qualifications effectively.”
On May 29th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Appointee in the Field of Human Liver Disease (Approval Notice).
General Field: Human Liver Disease
Position at the Time of Case Filing: Postdoctoral Appointee
Country of Origin: Nepal
State of Residence at the Time of Filing: Indiana
Approval Notice Date: May 29th, 2025
Processing Time: 16 days (Premium Processing Requested)
Case Summary:
Our client has emerged as a leading voice in the field of liver disease, particularly through his groundbreaking work on nonalcoholic fatty liver disease (NAFLD), liver regeneration, and gene regulation. His investigations have yielded original discoveries and novel approaches that have reshaped the understanding of disease mechanisms and therapeutic options. His research addresses one of the world’s most urgent health crises: the rapidly increasing prevalence of chronic liver disease.
Scientific Contributions with Global Reach
His work has led to several high-impact discoveries, including insights into apoptosis in liver cancer, miRNA regulation in NAFLD, and the influence of sex and aging in MASLD. These contributions offer important avenues for targeted therapy and public health intervention. One expert emphasized his impact in their exact words:
“His approach to medicine is also a feasible complementary treatment option for fighting viral infections like HBV, which helps to improve the efficacy of conventional treatments and increase precision medicine. Since cancer is the leading cause of mortality in the U.S., combating its prevalence is of utmost concern for the healthcare system. [Client]'s work must continue uninterrupted to benefit public health and strengthen the nation's healthcare system.”
Recognized by Peers and Institutions AlikeHis work has earned research support from prestigious institutions, including the Department of Science and Technology and the Department of Biotechnology of the Government of India, as well as the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), highlighting both its international recognition and alignment with U.S. healthcare priorities.
His publication record includes 14 peer-reviewed journal articles (3 first-authored) and 6 abstracts (1 first-authored), with 353 citations by researchers across at least 38 countries. He has also completed 26 journal peer reviews, reflecting his standing in the scientific community.
Seamless Approval with NAILG’s Strategic Expertise
When pursuing the EB-1A petition, our client partnered with the North America Immigration Law Group (NAILG), which built a compelling case demonstrating his extraordinary ability. NAILG emphasized not only his scientific productivity but also the direct relevance of his research to critical U.S. healthcare challenges, particularly those related to liver disease, metabolic dysfunction, and precision medicine.
Approved in Just 16 Days, No RFE
The petition was approved in only 16 days under Premium Processing, with no Request for Evidence (RFE). This swift and seamless approval reflects both the strength of our client’s qualifications and the effectiveness of NAILG’s legal strategy. He is now positioned to continue making high-impact contributions to biomedical research in the United States.